Test, measure, and validate tools that empower patients as core members of their oncology care team
Let’s research patient empowerment together
The Patient Empowerment Alliance (P.E.A.) is an innovative part of the GSK Supported Studies Program. It was created to test, measure, and validate tools that empower patients as core members of their oncology care team.
More power behind patient empowerment
What is the P.E.A.?
The P.E.A., also known as the Patient Empowerment Alliance, is an innovative part of GSK’s Supported Studies Program.
The P.E.A. is a global initiative created to:
Why was the P.E.A. created?
While active patient engagement is an essential part of cancer care, there are barriers for many patients to taking a purposeful role in their own treatment. We saw an opportunity to research patient empowerment the same way as any therapeutic intervention.
What type of research does the P.E.A. support?
The P.E.A. has 3 key areas of interest:
With a particular focus on 1L+ ovarian cancer, endometrial cancer, myelofibrosis, rectal cancer, lung cancer, and multiple myeloma, proposals that include at-risk and underserved populations will be given priority.
What kinds of studies have been accepted?
While we can’t share specific details about ongoing P.E.A. Supported Studies, here are a few examples of accepted initiatives:
Supported Study 1
| P.E.A. area of interest: | Care coordination |
|---|---|
| Disease state: | Ovarian cancer |
| Objective: | To evaluate an artificial intelligence-based care pathway recommendation platform customized for ovarian cancer patients to improve quality of life. |
| Endpoint: | Change over time in the Function and Well-being Subscale score, as measured by the National Comprehensive Cancer Network®/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18), obtained from baseline to 12 months. |
Supported Study 2
| P.E.A. area of interest: | Care coordination |
|---|---|
| Disease state: | Endometrial cancer, Colorectal cancer, Ovarian cancer |
| Objective: | To establish and evaluate the impact of a direct-to-patient pathway for unselected genetic testing at diagnosis compared with the current mainstreaming pathway. |
| Endpoint: | Uptake of genetic testing, defined as the number of participants who receive genetic testing divided by the number of participants offered genetic testing. |
Supported Study 3
| P.E.A. area of interest: | Patient health literacy |
|---|---|
| Disease state: | Multiple myeloma |
| Objective: | To evaluate the impact of a multiple myeloma focused knowledge-sharing platform in patients with relapsed disease. |
| Endpoint: | Change from baseline in patient activation—a patient’s willingness and ability to take independent actions to manage their health and care. |
How can I take the next step?
Speak with your GSK partner or send us an email at: Supported.Studies@gsk.com.
Or if you’re ready, you can submit a proposal now:
SE-GBL-ON-WCNT-200001 | April 2023